Stock Market Reviews

AXSM (Axsome Therapeutics, Inc.) News

Get the latest news, insights, and market updates on AXSM (Axsome Therapeutics, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• HALO or AXSM: Which Is the Better Value Stock Right Now?
  HALO vs. AXSM: Which Stock Is the Better Value Option?
  Jan 9, 2026 - $AXSM
• Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
  Significant updates from the FDA toward the end of 2025 have rallied investor interest in Axsome and Innoviva, two high-potential biotech names for 2026.
  Jan 8, 2026 - $AXSM
• 2 Healthcare Stocks to Buy for 2026 and Beyond
  These could be the next biotech giants.
  Jan 8, 2026 - $AXSM
• Why Axsome Therapeutics (AXSM) Is Up 17.5% After Dual FDA Boosts For AXS-05 And AXS-12 – And What's Next
  Axsome Therapeutics recently reported that the FDA accepted its supplemental application and granted priority review for AXS-05 to treat agitation in Alzheimer’s disease, while also confirming that its data package for AXS-12 in narcolepsy is sufficient to support a New Drug Application filing. These twin regulatory milestones highlight Axsome’s growing late-stage CNS pipeline breadth, with potential for expanded indications that could reshape its long-term revenue mix if approvals are...
  Jan 5, 2026 - $AXSM
• Axsome Therapeutics (AXSM): Reassessing Valuation After Key FDA Milestones for AXS-05 and AXS-12
  Axsome Therapeutics (AXSM) has quickly moved onto investors' radar after the FDA accepted a priority review for AXS-05 in Alzheimer’s agitation and signaled support for an NDA filing for narcolepsy drug AXS-12. See our latest analysis for Axsome Therapeutics. Those regulatory wins have sparked a sharp re-rating, with Axsome’s 7 day share price return of 17.52% feeding into a 90 day share price return of 48.98% and a 1 year total shareholder return of 106.70%. This suggests momentum is firmly...
  Jan 5, 2026 - $AXSM
• Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar?
  Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
  Jan 2, 2026 - $AXSM
• AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation
  Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.
  Jan 2, 2026 - $AXSM
• Why Axsome Therapeutics Stock Rocketed Higher to End 2025
  Axsome Therapeutics shareholders got a New Year's gift from the FDA.
  Dec 31, 2025 - $AXSM
• US Equity Indexes Lower Amid Mixed Economic Data
  US equity indexes fell on Wednesday, with all sectors posting declines amid mixed macroeconomic data
  Dec 31, 2025 - $AXSM
• US Equity Indexes Lower Amid Mixed Macro Data
  US equity indexes fell in recent Wednesday trading, with all sectors posting declines, amid mixed ma
  Dec 31, 2025 - $AXSM